within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01ED05_Lorlatinib;

model Lorlatinib
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.81,
    Cl = 2.3888888888888887e-06,
    adminDuration = 600,
    adminMass = 100 / 1000000,
    adminCount = 1,
    Vd = 0.305,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.004,
    Tlag = 10.020000000000001,
    Vdp = 1.77,
    k12 = 2.25e-05,
    k21 = 2.25e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Lorlatinib</td></tr><tr><td>ATC code:</td><td>L01ED05</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>100</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>305</td><td>L</td></tr>
    <tr><td>clearance:</td><td>8.6</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Lorlatinib is a third-generation, reversible, macrocyclic tyrosine kinase inhibitor targeting anaplastic lymphoma kinase (ALK) and ROS1, approved for use in non-small cell lung cancer (NSCLC) patients with ALK-positive tumors, particularly after resistance to earlier-generation ALK inhibitors.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with ALK-positive advanced NSCLC after oral administration under fasted conditions.</p><h4>References</h4><ol><li><p>Damoiseaux, D, et al., &amp; Dorlo, TPC (2022). Predictiveness of the Human-CYP3A4-Transgenic Mouse Model (Cyp3aXAV) for Human Drug Exposure of CYP3A4-Metabolized Drugs. <i>Pharmaceuticals (Basel, Switzerland)</i> 15(7) –. DOI:<a href=\"https://doi.org/10.3390/ph15070860\">10.3390/ph15070860</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35890158/\">https://pubmed.ncbi.nlm.nih.gov/35890158</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01ED05 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Lorlatinib;
